(secondQuint)Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia.

 TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd.

 TAK-085 contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl docosahexaenoic acid (DHA-E)).

 This is a phase 3, open-label, randomized study to evaluate the efficacy and safety of TAK-085.

 In addition, EPA-E is also administered for 52 weeks for reference to evaluate the safety of TAK-085 in participants with hypertriglyceridemia who are undergoing lifestyle modification.

 The study period is a total of 56 weeks, comprised of a 4- week screening period and 52 weeks of treatment.

.

 Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia@highlight

The purpose of this study is to determine the safety and efficacy of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.

